MD
MDCX.US Medicus Pharma Ltd. Common Stock
- Market cap
- USD 3.75M
- P/E
- -
- P/B
- 11.97x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MDCX.US undervalued?
Graham numberThe Graham number of Medicus Pharma Ltd. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medicus Pharma Ltd. Common Stock fundamental analysis
No fundamental analysis for Medicus Pharma Ltd. Common Stock yet.
Medicus Pharma Ltd. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed …
Full company profileMedicus Pharma Ltd. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medicus Pharma Ltd. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2015 | 2016 | 2017 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 12.6M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.34M | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
| Operating Income | -506K | -3.42K | -5.77K | -136K | -1.44M | -978K | -4.73M | -11.2M | -18.4M | -46.0M |
| EBITDA | - | - | - | - | -1.94M | -1.17M | 1.80M | -11.2M | -25.2M | -47.3M |
| Net Income | -694K | -3.42K | -5.77K | -139K | -2.06M | -1.69M | -5.31M | -11.2M | -25.4M | -47.8M |
| EPS | - | - | - | - | -13 | -10 | -33 | -47 | -73 | -37 |
| Balance Sheet | ||||||||||
| Total Assets | 3.00M | - | - | 40.6K | 78.5K | 283K | 1.89M | 5.65M | 10.1M | 14.5M |
| Total Liabilities | 5.00M | 3.42K | 9.18K | 103K | 10.6M | 12.5M | 782K | 2.51M | 10.0M | 25.0M |
| Shareholders' Equity | -2.00M | - | - | -62.7K | -10.5M | -12.2M | 1.11M | 3.13M | -67.6K | -10.5M |
| Cash & Short-term Investments | 5.41K | - | - | 40.6K | 78.5K | 268K | 1.72M | 4.16M | 8.71M | 5.02M |
| Total Debt | - | - | - | - | 668K | 1.53M | - | 322K | 4.00M | 21.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.20M | -3.10K | -3.10K | -66.0K | -1.45M | -1.06M | -4.16M | -10.2M | -22.8M | -33.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.67 |
| Free Cash Flow | - | - | - | - | -1.45M | -1.06M | -4.16M | -10.2M | -22.8M | -39.8M |
| Ratios | ||||||||||
| ROE | - | - | - | - | - | - | -478.2% | -355.9% | - | - |
| ROA | -23.1% | - | - | -342.2% | -2,617.7% | -598.8% | -280.8% | -197.6% | -252.1% | -328.7% |
| Net Profit Margin | -5.5% | - | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | - | - | 0.10x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medicus Pharma Ltd. Common Stock dividends
Medicus Pharma Ltd. Common Stock has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on Oct 12, 2026.
Who owns Medicus Pharma Ltd. Common Stock
- Insiders 14.77%
- Institutions 3.47%
- Public & others 81.76%
- Shares outstanding 1.92M
- Free float 1.61M
Top funds holding MDCX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| 1290 VT Micro Cap K | 2.74K | 0.00% | 0.00% | May 2026 |
Top institutions holding MDCX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Interchange Capital Partners, LLC | 1.59M | 2.21% | -4.51% | Jun 2026 |
| Jane Street Group LLC | 334K | 0.47% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 243K | 0.34% | 0.00% | Jun 2026 |
| Sterling Investment Advisors Ltd | 100K | 0.14% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 52.6K | 0.07% | +9.35% | Jun 2026 |
| May Hill Capital, LLC | 50.6K | 0.07% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 31.5K | 0.04% | 0.00% | Jun 2026 |
| Stifel Financial Corp | 30.0K | 0.04% | 0.00% | Jun 2026 |
| Bryn Mawr Trust Company | 25.6K | 0.04% | -50.00% | Jun 2026 |
| JPMorgan Chase & Co | 25.6K | 0.04% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 25.1K | 0.04% | +40.83% | Jun 2026 |
| Smithfield Trust Co | 24.6K | 0.03% | +114.41% | Jun 2026 |
| Stratos Wealth Partners, LTD | 21.0K | 0.03% | 0.00% | Jun 2026 |
| LPL Financial Corp | 17.5K | 0.02% | +12.17% | Jun 2026 |
| StoneX Group Inc | 17.1K | 0.02% | +12.51% | Jun 2026 |
| Foundations Investment Advisors, LLC | 11.0K | 0.02% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 7.50K | 0.01% | -11.76% | Jun 2026 |
| Royal Bank of Canada | 1.06K | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.02K | 0.00% | -81.31% | Jun 2026 |
| Mercer Global Advisors Inc. | 500.00 | 0.00% | 0.00% | Jun 2026 |
Medicus Pharma Ltd. Common Stock company profile
- Company name
- Medicus Pharma Ltd. Common Stock
- Ticker
- MDCX.US
- ISIN
- CA58471K2020
- Exchange
- USA Stocks
- Listed since
- Feb 3, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- 300 Conshohocken State Road, West Conshohocken, PA, United States, 19428
- Phone
- 610 636 0184
- Website
- medicuspharma.com
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
Medicus Pharma Ltd. Common Stock management
7- Dr. Raza Bokhari M.B.A., M.D.CEO & Executive Chairman · born 1968
- Dr. Edward J. Brennan Jr., F.A.C.S., M.D.Chief Scientific Officer and Head of R&D Program · born 1961
- Dr. Faisal Mehmud M.D.Chief Medical Officer · born 1975
- Mr. Andrew Alasdair SmithChief Operating Officer · born 1969
- Ms. Anna Baran-Djokovic J.D.Senior Vice President of Investor Relations
- Ms. Viktoria SlepeniukSenior Vice President of Public Relations
- Ms. Maryann AdessoChief of Staff & Corporate Secretary